Most Read Articles
09 Jan 2021
Infection with the human respiratory syncytial virus may lead to a severe respiratory disease which, in the long-run, could impair memory and language-learning, a recent study has found.
Stephen Padilla, 12 Jan 2021
Renin-angiotensin system inhibitors perform better than calcium channel blockers (CCB) at decreasing albuminuria among diabetic and hypertensive patients with nephropathy, according to the results of a systematic review and meta-analysis.
5 days ago
Nearly one-fifth of patients with rheumatoid arthritis (RA) develop ocular complications, as do one-quarter to one-third of those with connective tissue diseases and vasculitis, according to a recent study.
6 days ago
Among patients with coronary artery disease (CAD), colchicine use may suppress risk of future cardiovascular events, reports a new meta-analysis.

Product Highlight - Saxenda

16 Sep 2020

Active ingredient: 1 ml of solution contains 6 mg of liraglutide. One pre-filled pen contains 18 mg liraglutide in 3 mL

Indications:
Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of
≥30 kg/m² (obese), or
≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

Dosage & Administration:
The starting dose is 0.6 mg daily. The dose should be increased to 3.0 mg daily in increments of 0.6 mg with at least one week interval to improve gastro-intestinal tolerability. Saxenda® is administered once daily at any time, independent of meals, subcutaneously injected in the abdomen, thigh or upper arm, preferably around the same time every day.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
09 Jan 2021
Infection with the human respiratory syncytial virus may lead to a severe respiratory disease which, in the long-run, could impair memory and language-learning, a recent study has found.
Stephen Padilla, 12 Jan 2021
Renin-angiotensin system inhibitors perform better than calcium channel blockers (CCB) at decreasing albuminuria among diabetic and hypertensive patients with nephropathy, according to the results of a systematic review and meta-analysis.
5 days ago
Nearly one-fifth of patients with rheumatoid arthritis (RA) develop ocular complications, as do one-quarter to one-third of those with connective tissue diseases and vasculitis, according to a recent study.
6 days ago
Among patients with coronary artery disease (CAD), colchicine use may suppress risk of future cardiovascular events, reports a new meta-analysis.